RT Journal Article
SR Electronic
T1 Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 595
OP 600
DO 10.1212/WNL.0000000000002950
VO 87
IS 6
A1 Wei Li
A1 Shannon L. Risacher
A1 Edgar Huang
A1 Andrew J. Saykin
A1 For the Alzheimer's Disease Neuroimaging Initiative
YR 2016
UL http://n.neurology.org/content/87/6/595.abstract
AB Objective: We investigated type 2 diabetes mellitus (T2DM) as a risk factor for brain atrophy and glucose hypometabolism in older adults with or at risk of cognitive impairment.Methods: Participants with the T2DM were identified from the Alzheimer's Disease Neuroimaging Initiative (ADNI-1/GO/2 cohorts). Analysis of covariance models were used to compare participants with and without T2DM, controlling for potential confounding factors.Results: Whole brain volume and whole brain [18F]-fluorodeoxyglucose (FDG) uptake were significantly different as a function of T2DM status, independent of baseline clinical diagnosis. On post hoc analysis, a lower whole brain volume was seen in participants with both mild cognitive impairment (MCI) and T2DM (n = 76) compared with participants who had MCI but not T2DM (n = 747; p = 0.009). Similarly, mean FDG uptake in gray matter and white matter was lower in participants with both MCI and T2DM (n = 72) than in participants with MCI without T2DM (n = 719; p = 0.04). Subsequent regional analysis revealed that the decreased FDG uptake in participants with both MCI and T2DM was mainly manifested in 3 brain regions: frontal lobe, sensory motor cortex, and striatum.Conclusions: T2DM may accelerate cognition deterioration in patients with MCI by affecting glucose metabolism and brain volume.AD=Alzheimer disease; ADNI=Alzheimer's Disease Neuroimaging Initiative; CI=confidence interval; FDG=[18F]-fluorodeoxyglucose; HC=healthy control; MCI=mild cognitive impairment; SUVR=standardized uptake value ratio; SVD=small vessel disease; T2DM=type 2 diabetes mellitus